This topic contains 0 replies, has 1 voice, and was last updated by 
-
Posts
-
An antibody-drug conjugate (ADC) is a type of targeted cancer therapy that uses monoclonal antibodies to deliver potent cytotoxic drugs directly to cancer cells. The monoclonal antibody specifically targets proteins or antigens that are overexpressed on the surface of cancer cells. Once the antibody binds to the cancer cell, the cytotoxic drug, which is attached to the antibody, is released inside the cell, leading to the destruction of the cancer cell. This approach allows for more precise targeting of cancer cells while minimizing damage to healthy cells, potentially reducing side effects compared to traditional chemotherapy. ADCs have shown promise in the treatment of various types of cancer and are an active area of research and development in oncology.
“According to Roots Analysis, the Antibody Drug Conjugate Market is estimated to be worth USD 7.72 billion. The market is forecasted to grow at a compound annual growth rate (CAGR) of 9.63% in the forecast period.
The report encompasses the global industry’s size, current trends, regional market share, demand, recent advancements, and potential business prospects. The report’s title is “Antibody Drug Conjugate Market Size, Revenue Growth by 2035.’’Antibody Drug Conjugate Market Segmentation:
The “Antibody Drug Conjugate Market (7th Edition), 2023-2035: Distribution by Target Disease Indication (Breast Cancer, B-cell Lymphoma, Lung Cancer, Multiple Myeloma, Acute Lymphoblastic Leukemia, Gastric Cancer, Renal Cancer, Cervical Cancer and Other Target Disease Indications), Therapeutic Area (Hematological Cancer and Solid Tumor), Linker (Valine-Citrulline, Succinimidyl-4-(N-Maleimidomethyl) Cyclohexane-1-Carboxylate, Tetrapeptide-based Linker, Maleimide, Maleimidocaproyl, Valine-Alanine, Hydrazone (4-(4-Acetylphenoxy) Butanoic Acid (AcBut) and Other Linkers), Payload (Monomethyl Auristatin E, DM1, Duocarmycin, SN-38 / Irinotecan, Monomethyl Auristatin F, SG3199, Ozogamicin, DM4 and Other Payloads), Target Antigens (HER-2 (ERBB2), CD79b, Trop-2, BCMA (TNFRSF17 / BCM), CD19, CD22, Tissue Factor, CD30, CEACAM5, Nectin 4 and Others).Regional Analysis of the Antibody Drug Conjugate Market
In terms of geographical segmentation, the Antibody Drug Conjugate Market is divided into North America, Europe, Asia-pacific.. The report features an extensive study of the current market landscape, market size and future opportunities for the antibody drug conjugate companies either developing the drugs or providing the necessary ADC technology, during the forecast period.
The following are the major objectives of the study:
• To delineate, depict, and predict the Antibody Drug Conjugate Market’s attributes based on Target Disease Indication, Therapeutic Area and Key Geographical Regions.
• To furnish comprehensive information regarding the key factors influencing Industry growth, encompassing drivers, limitations, opportunities, and challenges.
• To conduct a strategic examination of micro-industries, focusing on their individual growth patterns, prospects, and contributions to the broader industry.
• To scrutinize Industry opportunities for key stakeholders and provide an in-depth analysis of the competitive landscape among major industry leaders.
• To project the dimensions of Industry segments across major regions: North America, Europe, Asia-pacific.
• To outline the profiles of key players in the industry and thoroughly assess their market shares and core competencies.The key companies in the Antibody Drug Conjugate Market are.
ADC Therapeutics, Astellas Pharma, AstraZeneca, Byondis, Daiichi Sankyo, Genentech, Gilead Sciences, ImmunoGen, Pfizer, RemeGen. This market report includes an easily searchable excel database of all the antibody drug conjugate companies worldwide.Major Points in TOC:
1. Preface
2. Research Methodology
3. Introduction
4. Market Overview
5. Company And Drug Profiles
6. Key Opinion Leaders
7. Partnerships And Collaborations
8. Patent Analysis
9. Key Commmercialization Strategies
10. Success Protocol AnalysisTOC Continued…………….
Frequently Asked Questions
• How many antibody drug conjugates are available in the market?
• What are the most common antigens targeted by antibody drug conjugates?
• Which are the key companies in the antibody drug conjugate market?
• How big is the ADC market?
• Which region has the highest growth rate in the antibody drug conjugates market?To view more details on this report, click on the link:
https://www.rootsanalysis.com/reports/antibody-drug-conjugates-market/270.htmlAbout Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.Contact:
Ben Johnson
+1 (415) 800 3415
Ben.johnson@rootsanalysis.com
You must be logged in to reply to this topic.